EA201491780A1 - Мутанты c-raf, придающие резистентность к ингибиторам raf - Google Patents

Мутанты c-raf, придающие резистентность к ингибиторам raf

Info

Publication number
EA201491780A1
EA201491780A1 EA201491780A EA201491780A EA201491780A1 EA 201491780 A1 EA201491780 A1 EA 201491780A1 EA 201491780 A EA201491780 A EA 201491780A EA 201491780 A EA201491780 A EA 201491780A EA 201491780 A1 EA201491780 A1 EA 201491780A1
Authority
EA
Eurasian Patent Office
Prior art keywords
raf
inhibitors
giving resistance
mutants giving
mutants
Prior art date
Application number
EA201491780A
Other languages
English (en)
Other versions
EA028135B1 (ru
Inventor
Раджи Энтони
Кэролайн Эмери
Леви А. Гаррауэй
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк.
Publication of EA201491780A1 publication Critical patent/EA201491780A1/ru
Publication of EA028135B1 publication Critical patent/EA028135B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Изобретение относится к нуклеиновым кислотам и белкам, имеющим мутантную последовательность C-RAF, и способам идентификации пациентов, имеющих рак, которые вероятно получат пользу от комбинированной терапии, и способам лечения.
EA201491780A 2012-03-28 2013-03-07 Мутанты c-raf, придающие резистентность к ингибиторам raf EA028135B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616999P 2012-03-28 2012-03-28
US201261708372P 2012-10-01 2012-10-01
PCT/US2013/029513 WO2013148100A1 (en) 2012-03-28 2013-03-07 C-raf mutants that confer resistance to raf inhibitors

Publications (2)

Publication Number Publication Date
EA201491780A1 true EA201491780A1 (ru) 2015-01-30
EA028135B1 EA028135B1 (ru) 2017-10-31

Family

ID=47892065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491780A EA028135B1 (ru) 2012-03-28 2013-03-07 Мутанты c-raf, придающие резистентность к ингибиторам raf

Country Status (15)

Country Link
US (5) US9629839B2 (ru)
EP (3) EP2831589B1 (ru)
JP (3) JP6348898B2 (ru)
KR (1) KR20140139510A (ru)
CN (1) CN104204806B (ru)
AU (1) AU2013240483B2 (ru)
BR (1) BR112014023496A2 (ru)
CA (1) CA2864169A1 (ru)
EA (1) EA028135B1 (ru)
ES (3) ES2908078T3 (ru)
MX (1) MX351945B (ru)
PL (1) PL2831589T3 (ru)
PT (1) PT2831589T (ru)
TR (1) TR201808010T4 (ru)
WO (1) WO2013148100A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008458A (es) 2017-01-17 2019-12-02 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
KR102537840B1 (ko) 2018-07-13 2023-05-31 삼성전자 주식회사 서버 장치 및 다른 장치들의 위치 정보를 수집하는 방법
WO2020163771A1 (en) * 2019-02-08 2020-08-13 Portage Glasgow Limited Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides
US20230183810A1 (en) * 2020-05-04 2023-06-15 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
WO2005009367A2 (en) 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
US20070105114A1 (en) 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
MX2009002710A (es) 2006-09-18 2009-03-25 Boehringer Ingelheim Int Metodos para tratar canceres que portan mutaciones de egfr.
EP2102362B1 (en) 2006-11-16 2012-07-04 Mount Sinai School of Medicine of New York University Compositions and methods for detecting noonan syndrome
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2791247C (en) * 2010-03-09 2019-05-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Also Published As

Publication number Publication date
KR20140139510A (ko) 2014-12-05
AU2013240483B2 (en) 2018-07-26
PT2831589T (pt) 2018-06-20
JP2015513901A (ja) 2015-05-18
ES2673070T3 (es) 2018-06-19
EP3693741B1 (en) 2022-01-05
ES2908078T3 (es) 2022-04-27
EP3333575A1 (en) 2018-06-13
US11788151B2 (en) 2023-10-17
US20210388325A1 (en) 2021-12-16
JP2018110594A (ja) 2018-07-19
WO2013148100A1 (en) 2013-10-03
US9629839B2 (en) 2017-04-25
CN104204806A (zh) 2014-12-10
MX351945B (es) 2017-11-03
EP3693741A1 (en) 2020-08-12
US20240093310A1 (en) 2024-03-21
PL2831589T3 (pl) 2018-10-31
BR112014023496A2 (pt) 2017-07-18
JP2020103291A (ja) 2020-07-09
AU2013240483A1 (en) 2014-08-28
ES2790896T3 (es) 2020-10-29
CA2864169A1 (en) 2013-10-03
US20150133478A1 (en) 2015-05-14
EP2831589B1 (en) 2018-04-18
EP2831589A1 (en) 2015-02-04
JP6661685B2 (ja) 2020-03-11
US20190142830A1 (en) 2019-05-16
EP3333575B1 (en) 2020-02-26
US20170204383A1 (en) 2017-07-20
MX2014011686A (es) 2015-06-04
CN104204806B (zh) 2016-02-03
JP6348898B2 (ja) 2018-06-27
TR201808010T4 (tr) 2018-06-21
EA028135B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
EP3289082A4 (en) Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
EA201291206A1 (ru) Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
MD4733C1 (ru) Антитела анти-TIGIT
DOP2014000084A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2016001186A (es) Diagnostico y terapia de cancer que implica celulas madre cancerosas.
EA202193044A2 (ru) Способы лечения таупатии
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201690529A1 (ru) Способы модификации клетки-хозяина
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
EA201691314A1 (ru) Терапевтические способы и композиции

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU